COMMUNIQUÉ DE PRESSE publié le 04/01/2024 à 12:30, il y a 2 années 3 mois Zomedica Announces Publication of Research Validating Better Patient Acceptance of PulseVet(R) Electro-hydraulic Shock Wave Therapy without Sedation Utilizing Novel “X-Trode” Handpiece Zomedica Corp. announced the publication of an article validating the ability to better utilize PulseVet electro-hydraulic shock wave therapy in awake canine patients without sedation. The article describes the use of a novel shockwave trode, reinforcing current clinical evidence on the effectiveness of electro-hydraulic shock wave therapy for various indications. The article was written by Dr. Gina L. Joseph and team at Colorado State University and is available on Frontiers in Veterinary Science. In addition, CSU is evaluating PulseVet therapy for slowing the progression of canine osteoarthritis, with expected results later in 2024. The ability to treat patients without sedation using X-Trode is seen as a major advancement. Zomedica's Vice President of Clinical and Veterinary Affairs, Adrian Lock, expressed excitement for the upcoming study to further validate the therapy's efficacy. The company's CEO, Larry Heaton, believes the publication will accelerate the acceptance of shock wave therapy for small animal patients. PulseVet's shock wave therapy harnesses high-energy sound waves to stimulate cells, promoting healing growth factors. Zomedica's commitment to advancing veterinary care is evident through ongoing clinical studies and product innovations. The company's mission to address the unmet needs of clinical veterinarians underscores its dedication to animal welfare and better veterinary practice. For more information, readers can visit Zomedica's website. Zomedica Corp PulseVet Electro-hydraulic Shock Wave Therapy Veterinary Health Company Canine Patients Electro-hydraulic Shock Wave Therapy
COMMUNIQUÉ DE PRESSE publié le 18/12/2023 à 12:30, il y a 2 années 4 mois Zomedica Announces Expansion of Market Opportunity for TRUFORMA(R) Diagnostic Platform with Launch of Three New Assays for Commonly Performed Diagnostic Tests for Canine Gastrointestinal Disease
COMMUNIQUÉ DE PRESSE publié le 06/12/2023 à 12:30, il y a 2 années 4 mois Zomedica Announces Presentation of Clinical Data in Support of New Indications for PulseVet Shock Wave Therapy at Annual Meeting of American Association of Equine Practitioners Zomedica announces presentation of clinical data in support of new indications for Pulsevet shock wave therapy at annual meeting of American Association of Equine Practitioners Zomedica Pulsevet Shock Wave Therapy Veterinary Health Clinical Data
COMMUNIQUÉ DE PRESSE publié le 28/11/2023 à 12:30, il y a 2 années 4 mois Zomedica to Present at Noble Capital Markets' 19th Annual Emerging Growth Equity Conference
COMMUNIQUÉ DE PRESSE publié le 20/11/2023 à 12:30, il y a 2 années 5 mois Zomedica to Present at the 35th Annual Piper Sandler Healthcare Conference
COMMUNIQUÉ DE PRESSE publié le 13/11/2023 à 22:20, il y a 2 années 5 mois Zomedica Announces Record Third Quarter 2023 Financial Results: Revenue up 31% to $6.3 Million; 69% Gross Margin, and $118 Million in Liquidity, while Making Strategic Acquisitions of Structured Monitoring Products and Qorvo Biotechnologies
COMMUNIQUÉ DE PRESSE publié le 02/11/2023 à 11:30, il y a 2 années 5 mois Zomedica to Report Third Quarter 2023 Financial Results and Provide Business Update on November 13 at 4:30 p.m. ET
COMMUNIQUÉ DE PRESSE publié le 10/10/2023 à 06:00, il y a 2 années 6 mois Zomedica to Participate in the Lytham Partners Fall 2023 Investor Conference
COMMUNIQUÉ DE PRESSE publié le 05/10/2023 à 12:30, il y a 2 années 6 mois Zomedica Announces Acquisition of TRUFORMA Platform Developer Qorvo Biotech LLC, Accelerating Timeline to Gain Control of Manufacturing and Research & Development
COMMUNIQUÉ DE PRESSE publié le 14/09/2023 à 12:30, il y a 2 années 7 mois Zomedica Announces Expansion of Market Opportunity for TRUFORMA(R) Diagnostic Platform with Launch of First-and-only Point of Care eACTH Assay for Diagnosis and Management of Cushing’s Disease in Horses
Publié le 22/04/2026 à 07:00, il y a 9 heures 53 minutes Chiffre d'affaires 1er trimestre 2026. 229,5M€ à devises constantes. 215,5 M€ à devises courantes.
Publié le 22/04/2026 à 07:00, il y a 9 heures 53 minutes Q1 2026 sales. €229.5m at constant exchange rates. €215.5m at current exchanges rates
Publié le 21/04/2026 à 19:15, il y a 21 heures 38 minutes AXA - Description of the Company’s share repurchase program
Publié le 22/04/2026 à 16:00, il y a 53 minutes Datavault AI Further Expands IP Portfolio with New Patent Issuance and Notices of Allowance
Publié le 22/04/2026 à 15:15, il y a 1 heure 38 minutes Karbon-X Highlights SkyXero on Earth Day, Bringing Real-Time Climate Action to Travel
Publié le 22/04/2026 à 13:45, il y a 3 heures 8 minutes Amarc Announces Listing on Frankfurt Stock Exchange
Publié le 22/04/2026 à 13:30, il y a 3 heures 23 minutes ZTEST Electronics Inc. Announces Its Intention to Effect a Normal Course Issuer Bid
Publié le 22/04/2026 à 13:30, il y a 3 heures 23 minutes Copper Road Announces Engagement of George Mannard
Publié le 22/04/2026 à 15:30, il y a 1 heure 23 minutes Deutsche Postbank Funding Trust III - Annual Report 2025
Publié le 22/04/2026 à 15:20, il y a 1 heure 32 minutes Aurise Foundation Launches XAUE, Unlocking Yield for RWA Gold
Publié le 22/04/2026 à 15:20, il y a 1 heure 32 minutes Treballadors pel Lloguer Turístic welcomes CJEU AG opinion on arbitrary short-term rental restrictions
Publié le 22/04/2026 à 15:10, il y a 1 heure 42 minutes Prophix® Launches Next Wave of Prophix One™ Agents, Defining the Delegation Era for Finance
Publié le 22/04/2026 à 15:05, il y a 1 heure 47 minutes Precisely Brings Governed AI to Customer Communications in EngageOne RapidCX